Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14210151 | 1.00 | TUBB1 (0.53) | TUBB1PDF | |
| SCHEMBL57439 | 1.00 | TUBB1 (0.53) | TUBB1PDF | |
| SCHEMBL12202130 | 0.92 | TUBB1 (0.44) | TUBB1PDF | |
| SCHEMBL88664 | 0.87 | TUBB1 (0.41) | TUBB1 | |
| SCHEMBL57978 | 0.87 | TUBB1 (0.41) | TUBB1 | |
| SCHEMBL58920 | 0.86 | TUBB1 (0.53) | TUBB1PDF | |
| SCHEMBL58144 | 0.85 | TUBB1 (0.56) | TUBB1 | |
| SCHEMBL57850 | 0.85 | TUBB1 (0.58) | TUBB1PDF | |
| SCHEMBL58626 | 0.85 | TUBB1 (0.54) | TUBB1PDF | |
| SCHEMBL14210202 | 0.85 | TUBB1 (0.54) | TUBB1PDF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| EP-2374454-A1 | Hemiasterlin derivatives and uses thereof in the treatment of cancer | Eisai R&D Management Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | DHCR7, HSD17B7, HCCS | TUBB1 1330/4885PDF 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.